Social Issues

Stable supply of effective and safe pharmaceuticals

Contributing to women's advancement in society

Addressing unmet medical needs

Animal health

Extending healthy lifespans

11 material issues

Contribution to women's health

Contribution to animal health, etc.

Input

Financial capital
Net sales: ¥60.4 billion
Operating profit margin: 8.4%
ROE: 8.2%

Manufactured capital
Capital expenditures: ¥1.2 billion
Production base: Iwaki Factory

Intellectual capital
R&D expenses: ¥4.2 billion

Natural capital
CO_2 emissions: 10,780t-CO_2
Electricity usage: 10,702 thousand kWh
Water usage: 138.73 thousand km³

Social capital
Main offices: 23 locations

Human capital
Number of employees: 747 (Consolidated)

Business Model



Output / Outcome

Economic Value

FY2025 targets
(Consolidated)
Net sales: ¥70.0 billion
Operating profit margin: 8%
ROE: 8%

Social Value

- Stable supply of high-quality pharmaceuticals
- Promotion of drug discovery through open innovation
- New initiatives and value provision for total healthcare
- Improving women's quality of life and promoting their advancement
- Coexistence between people and animals
- Improving health literacy
- Preventative medicine/Improvement of pre-symptomatic states

Vision

Total Healthcare Company with a Strong Foundation as a Specialty Pharma Company

Thorough corporate governance and compliance/Sustainable ESG management

Corporate Philosophy: Contribute toward the improvement of people's health and progress in society through the development of innovative products